The British journal of dermatology
-
Randomized Controlled Trial Multicenter Study
Successful treatment of moderate to severe plaque psoriasis with the PEGylated Fab' certolizumab pegol: results of a phase II randomized, placebo-controlled trial with a re-treatment extension.
Certolizumab pegol (CZP) is a PEGylated antitumour necrosis factor agent. ⋯ Treatment with CZP significantly improved psoriasis at week 12. Similar efficacy was observed at week 12 in patients receiving re-treatment for loss of response after drug withdrawal.